- Home
- WWR vs CMMB Comparison
WWR vs CMMB Comparison
Compare WWR & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WWR
- CMMB
- Stock Information
- Founded
- WWR 1977
- CMMB 2004
- Country
- WWR United States
- CMMB Israel
- Employees
- WWR N/A
- CMMB N/A
- Industry
- WWR Metal Mining
- CMMB Biotechnology: Pharmaceutical Preparations
- Sector
- WWR Basic Materials
- CMMB Health Care
- Exchange
- WWR Nasdaq
- CMMB Nasdaq
- Market Cap
- WWR N/A
- CMMB 23.0M
- IPO Year
- WWR N/A
- CMMB N/A
- Fundamental
- Price
- WWR $0.59
- CMMB $1.16
- Analyst Decision
- WWR Strong Buy
- CMMB Strong Buy
- Analyst Count
- WWR 1
- CMMB 2
- Target Price
- WWR $2.00
- CMMB $8.50
- AVG Volume (30 Days)
- WWR 607.4K
- CMMB 182.0K
- Earning Date
- WWR 08-13-2025
- CMMB 08-20-2025
- Dividend Yield
- WWR N/A
- CMMB N/A
- EPS Growth
- WWR N/A
- CMMB N/A
- EPS
- WWR N/A
- CMMB N/A
- Revenue
- WWR N/A
- CMMB N/A
- Revenue This Year
- WWR N/A
- CMMB N/A
- Revenue Next Year
- WWR N/A
- CMMB N/A
- P/E Ratio
- WWR N/A
- CMMB N/A
- Revenue Growth
- WWR N/A
- CMMB N/A
- 52 Week Low
- WWR $0.45
- CMMB $0.87
- 52 Week High
- WWR $1.32
- CMMB $2.55
- Technical
- Relative Strength Index (RSI)
- WWR 58.04
- CMMB 38.60
- Support Level
- WWR $0.59
- CMMB $1.17
- Resistance Level
- WWR $0.63
- CMMB $1.20
- Average True Range (ATR)
- WWR 0.03
- CMMB 0.05
- MACD
- WWR -0.00
- CMMB 0.00
- Stochastic Oscillator
- WWR 50.00
- CMMB 16.46
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.